Humacyte, Inc. has announced the suspension and termination of its ATM prospectus, which was intended for the sale of up to $60 million of its common stock. This decision was communicated to TD Securities (USA) LLC, the agent for the sales agreement dated December 16, 2025. The company will not proceed with any further sales of its common stock under this agreement until a new prospectus or registration statement is filed. In conjunction with this announcement, Humacyte provided preliminary financial information for the year ended December 31, 2025. The company expects to report approximately $50.9 million in cash and cash equivalents, alongside total revenues of approximately $2.0 million, which includes $1.4 million in product revenue. Additionally, the company anticipates reporting 61 unit sales of its Symvess product for the same period. These preliminary figures are subject to final adjustments and have not been audited by PricewaterhouseCoopers LLP. The company has emphasized that these estimates should not be viewed as substitutes for finalized financial statements prepared in accordance with generally accepted accounting principles. Furthermore, Humacyte has provided operational updates, including a minimum purchase commitment of approximately $1.48 million for its Symvess product in Saudi Arabia, aimed at educating surgeons and evaluating the product in local hospitals. The company is also pursuing a marketing authorization application in Israel for the vascular trauma indication. Despite these developments, the suspension of the ATM prospectus raises concerns about the company's liquidity and ability to finance its operations effectively moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.